1. Home
  2. BEAM vs HUN Comparison

BEAM vs HUN Comparison

Compare BEAM & HUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$32.61

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Huntsman Corporation

HUN

Huntsman Corporation

HOLD

Current Price

$14.24

Market Cap

2.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
HUN
Founded
2017
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
BEAM
HUN
Price
$32.61
$14.24
Analyst Decision
Buy
Hold
Analyst Count
12
11
Target Price
$50.75
$12.09
AVG Volume (30 Days)
1.7M
4.3M
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
2.64%
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
$5,683,000,000.00
Revenue This Year
N/A
$3.08
Revenue Next Year
$33.77
$5.27
P/E Ratio
N/A
N/A
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$7.30
52 Week High
$36.44
$15.90

Technical Indicators

Market Signals
Indicator
BEAM
HUN
Relative Strength Index (RSI) 57.71 48.72
Support Level $26.23 $13.13
Resistance Level $34.29 $15.60
Average True Range (ATR) 1.88 0.62
MACD 0.13 -0.03
Stochastic Oscillator 82.27 47.64

Price Performance

Historical Comparison
BEAM
HUN

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About HUN Huntsman Corporation

Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.

Share on Social Networks: